olivLaw · US equity research
CG Oncology, Inc. CGON
Biological Products, (No Diagnostic Substances) · SIC 2836 · Vertical: Biological Products, (No Diagnostic Substances) (SIC 2836)
CG Oncology is a late-stage biopharmaceutical company developing cretostimogene, an investigational oncolytic immunotherapy given intravesically for non-muscle invasive bladder cancer. The company is nearing completion of its Biologics License Application with the FDA but has no approved products yet, and its net losses have been rising.
At the close of 04 Nov 2026, CG Oncology, Inc. (CGON) stock was 67.71 USD (+5.70% on the day), with market capitalisation 6.0 bn USD, beta 1.43, 52-week range 37.37–80.68 USD. Latest reported quarter (Q2 2026): revenue of 1.2 m USD, net income of -79.1 m USD, diluted EPS -0.90 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 57.5
- strong (55–70)
- Bollinger (20, 2)
- 59.41 – 66.08
- above the upper band · %B 1.24 · band width 10.6%
- SMA 50 / 200
- 68.57 / 66.06
- mixed trend
- MACD (12, 26, 9)
- -0.93 / -1.79
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −1.5% | −1.1% | −0.4 pp | — |
| 3 months | −6.5% | −0.5% | −6.1 pp | — |
| 6 months | −0.4% | +4.4% | −4.8 pp | — |
| Year to date | +63.1% | +12.3% | +50.8 pp | — |
| 1 year | +73.3% | +13.5% | +59.8 pp | +8.1% |
| 3 years | unavailable | +76.4% | unavailable | +3.1% |
| 5 years | unavailable | +63.7% | unavailable | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 43.0 k | 456.0 k | 52.0 k | 0 | 1.7 m | 2.3 m | 1.1 m | 1.2 m |
| Research & development | 19.6 m | 26.8 m | 27.5 m | 31.3 m | 27.9 m | 30.0 m | 43.7 m | 54.7 m |
| Operating income | -28.3 m | -38.0 m | -42.2 m | -48.7 m | -51.1 m | -48.7 m | -66.4 m | -86.4 m |
| Depreciation & amortisation | 21.0 k ≈ | 0 | 24.0 k | 156.0 k ≈ | 416.0 k ≈ | 849.0 k | 841.0 k | 850.0 k ≈ |
| Net income | -20.4 m | -31.8 m | -34.5 m | -41.4 m | -43.8 m | -41.3 m | -60.2 m | -79.1 m |
| Diluted EPS | -0.30 | -0.46 ≈ | -0.45 | -0.54 | -0.57 | -0.52 ≈ | -0.71 | -0.90 |
| Operating cash flow | -15.9 m ≈ | -20.7 m | -29.3 m | -28.0 m ≈ | -38.9 m ≈ | -36.2 m | -56.9 m | -46.4 m ≈ |
| Capex | -1.0 k ≈ | 209.0 k | 16.0 k | 14.0 k ≈ | 97.0 k ≈ | 7.0 k | 304.0 k | 468.0 k ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 204.0 k | 1.1 m | 4.0 m |
| Revenue YoY | unavailable | +458.3% | +254.7% |
| Net income | -48.6 m | -88.0 m | -161.0 m |
| Net income YoY | unavailable | unavailable | unavailable |
| Diluted EPS | -15.65 | -1.41 | -2.08 |
| Diluted EPS YoY | unavailable | unavailable | unavailable |
| net % | -23,827.0% | -7,729.5% | -3,985.0% |
| Free cash flow | unavailable | -78.9 m | -132.5 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 32.5 m USD
- Financial debt
- 3.0 m USD
- Net debt
- -29.5 m USD
- Equity
- 752.6 m USD
- Total assets
- 791.6 m USD
- Debt / equity
- 0.00x
- Current ratio
- 24.63x
- ROE
- -21.7%
- ROA
- -20.8%
- FCF margin
- -3,279.2%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Revenue | 204.0 k | 1.1 m | 4.0 m | SEC (XBRL)· 27 Feb 2026verified |
| Research & development | 45.8 m | 82.1 m | 116.6 m | SEC (XBRL)· 27 Feb 2026verified |
| Operating income | -55.4 m | -114.7 m | -190.8 m | SEC (XBRL)· 27 Feb 2026verified |
| Depreciation & amortisation | 17.0 k | 32.0 k | 1.4 m | SEC (XBRL)· 27 Feb 2026verified |
| EBITDA | -55.4 m ≈ | -114.6 m ≈ | -189.3 m ≈ | SEC (XBRL)· 27 Feb 2026derived |
| Income tax | 1.0 k | 1.0 k | -270.0 k | SEC (XBRL)· 27 Feb 2026verified |
| Net income | -48.6 m | -88.0 m | -161.0 m | SEC (XBRL)· 27 Feb 2026verified |
| Diluted EPS | -15.65 | -1.41 | -2.08 | SEC (XBRL)· 27 Feb 2026verified |
| Weighted average diluted shares | 4.3 m | 62.5 m | 77.3 m | SEC (XBRL)· 27 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Cash | 8.3 m | 257.1 m | 32.5 m | SEC (XBRL)· 27 Feb 2026verified |
| Inventories | — | 0 | 1.6 m | SEC (XBRL)· 27 Feb 2026verified |
| Current assets | 194.1 m | 754.2 m | 759.5 m | SEC (XBRL)· 27 Feb 2026verified |
| Property, plant & equipment, net | 69.0 k | 272.0 k | 15.6 m | SEC (XBRL)· 27 Feb 2026verified |
| Goodwill | — | 0 | 10.3 m | SEC (XBRL)· 27 Feb 2026verified |
| Intangibles (excl. goodwill) | — | 0 | 575.0 k | SEC (XBRL)· 27 Feb 2026verified |
| Total assets | 199.3 m | 754.8 m | 791.6 m | SEC (XBRL)· 27 Feb 2026verified |
| Accounts payable | 3.2 m | 6.5 m | 5.7 m | SEC (XBRL)· 27 Feb 2026verified |
| Long-term debt | — | 0 | 3.0 m | SEC (XBRL)· 27 Feb 2026verified |
| Current liabilities | 14.3 m | 21.4 m | 30.8 m | SEC (XBRL)· 27 Feb 2026verified |
| Total liabilities | 14.5 m | 21.4 m | 39.0 m | SEC (XBRL)· 27 Feb 2026verified |
| Equity | -123.1 m † | 733.4 m † | 752.6 m † | SEC (XBRL)· 27 Feb 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Operating cash flow | -45.7 m | -78.7 m | -132.3 m | SEC (XBRL)· 27 Feb 2026verified |
| Capex | — | 234.0 k | 134.0 k | SEC (XBRL)· 27 Feb 2026verified |
| Free cash flow | — | -78.9 m ≈ | -132.5 m ≈ | SEC (XBRL)· 27 Feb 2026derived |
| Investing cash flow | -121.2 m | -300.8 m | -245.8 m | SEC (XBRL)· 27 Feb 2026verified |
| Financing cash flow | 87.0 m | 628.3 m | 153.6 m | SEC (XBRL)· 27 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 4 of at least 6
- score weight coverage: 29.2% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 6.0 bn USD
Key indicators
Coverage and freshness
Score by group
29% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · the base of the ratio is not positive
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 4 of at least 6; score weight coverage: 29.2% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | -21.0% | 57 (vs peers) | 36% |
| Net margin · Quality | -3,602.7% | 10 (vs peers) | 21% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 22.2x | 100 (on a fixed band) | 14% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -3.0% | 0 (on a fixed band) | 29% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality40/100 · 2/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
CG Oncology, Inc. (CGON). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 4.0 m USD in 2025; YoY growth 254.7%; net margin -3,602.7%; ROE -26.4%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 4 of at least 6; score weight coverage: 29.2% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 22.2x
What contradicts it
- Net margin: -3,602.7%
- FCF yield: -3.0%
Not assessed (insufficient data or a ratio without meaning): FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Biological Products, (No Diagnostic Substances) (SIC 2836) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| AMGNAmgen Inc. | 258.8 bn | 27.7 | 78.4% | 24.1% | +10.0% | +39% / +77% |
| GILDGilead Sciences, Inc. | 216.4 bn | — | -22.3% | -12.5% | +2.4% | +39% / +128% |
| MRNAModerna, Inc. | 103.2 bn | — | -39.0% | -141.4% | −39.9% | +895% / +233% |
| ARGXArgenx Se | 57.6 bn | 47.6 | 20.2% | — | +254.4% | +2% / +107% |
| RVMDRevolution Medicines, Inc. | 43.2 bn | — | -93.6% | -946.8% | unavailable | +157% / +756% |
| BIIBBiogen Inc. | 37.6 bn | 108.8 | 1.9% | 3.4% | +2.2% | +40% / +9% |
| EXELExelixis, Inc. | 17.8 bn | 21.7 | 44.3% | 35.5% | +7.0% | +65% / +234% |
| TECHBio-Techne Corp | 11.4 bn | 62.7 | 9.0% | 15.0% | −0.4% | +13% / +16% |
| QGENQiagen N.V. | 11.0 bn | 26.2 | 11.6% | 20.3% | +5.7% | +6% / +20% |
| IBRXImmunitybio, Inc. | 9.5 bn | — | — | -598.6% | +668.3% | +278% / +143% |
| CGONCG Oncology, Inc. | 6.0 bn | — | -26.4% | -3,602.7% | +254.7% | +73% / unavailable |
| BEAMBeam Therapeutics Inc. | 2.9 bn | — | -11.3% | -73.9% | +120.0% | +10% / −1% |
| RXRXRecursion Pharmaceuticals, Inc. | 2.4 bn | — | -48.7% | -697.1% | +26.9% | −16% / −43% |
| NVAXNovavax Inc | 1.8 bn | — | — | -59.9% | +64.7% | +51% / +94% |
| TSHATaysha Gene Therapies, Inc. | 1.4 bn | — | -47.1% | -2,728.0% | +17.3% | −8% / +148% |
| INBXInhibrx Biosciences, Inc. | 1.3 bn | — | -1,773.6% | — | +550.0% | +3% / unavailable |
| EVAXEvaxion A | 1.2 bn | — | -100.2% | -102.4% | +125.1% | −50% / −93% |
| GLUEMonte Rosa Therapeutics, Inc. | 923.1 m | — | -42.7% | -560.9% | +63.5% | −33% / +249% |
| PRMEPrime Medicine, Inc. | 901.4 m | — | -373.3% | -4,056.4% | +55.3% | +30% / −32% |
| SLDBSolid Biosciences Inc. | 727.7 m | — | -76.9% | — | −40.6% | +20% / +131% |
| CCCCC4 Therapeutics, Inc. | 383.8 m | — | -48.1% | -289.4% | +1.0% | +15% / +91% |
| AUTLAutolus Therapeutics plc | 367.3 m | — | -133.0% | -238.7% | +644.9% | −2% / −68% |
| AGENAgenus Inc | 313.8 m | 2.6 | — | 69.3% | +10.4% | +53% / −55% |
| SABSSab Biotherapeutics, Inc. | 289.3 m | — | -11.3% | — | −100.0% | −19% / −67% |
| FATEFate Therapeutics Inc | 250.4 m | — | -60.7% | -1,941.1% | −51.2% | +83% / −16% |
1- and 3-year price returns: for CGON from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
CG Oncology is a late-stage biopharmaceutical company developing cretostimogene, an investigational oncolytic immunotherapy given intravesically for non-muscle invasive bladder cancer. The company is nearing completion of its Biologics License Application with the FDA but has no approved products yet, and its net losses have been rising 13.
SWOT
Strengths
- The company has a unique investigational product with a dual mechanism, Phase 3 data published in a leading journal, and Fast Track and Breakthrough Therapy designations from the FDA 12.
- Liquidity is strong, and the company aims to fund operations over a long horizon, giving it time to develop the product 3.
- The safety profile reported so far, with no treatment-related Grade 3 or higher events in the main study, supports the product's position against alternatives 1.
Weaknesses
- The company depends entirely on a single candidate, so a failed study or BLA could materially affect operations 1.
- The company generates no meaningful product sales, and net losses and operating expenses are rising from quarter to quarter 13.
- Manufacturing is outsourced to third parties, including a recently acquired entity, introducing execution and compliance risks 1.
Opportunities
- An approval in intermediate-risk NMIBC could open a larger market and an adjuvant indication with no currently FDA-approved options 1.
- The BCG shortage and reluctance toward cystectomy create a setting in which bladder-sparing therapies could gain share quickly 1.
- Combinations with other therapies, such as pembrolizumab or gemcitabine, could extend the product's usefulness beyond monotherapy 12.
Threats
- Intermediate results can differ from final ones, and a failure at PIVOT-006 could seriously limit the company's prospects 12.
- Litigation over a licence agreement, in which a court upheld the verdict in the company's favour but the counterparty continued challenging it, adds uncertainty 3.
- If regulators require additional studies, the commercial timeline could be delayed and costs increased 1.
Risks
- Single-product dependencehigh
The entire business depends on the success of cretostimogene, and any delay or rejection could seriously affect the company 1.
- Uncertainty of clinical resultshigh
Interim results are not necessarily predictive of final analyses, and data from ongoing studies could be revised 12.
- Regulatory approvalhigh
If the FDA requests further data or rejects the BLA, the commercial timeline could be significantly delayed 13.
- Shareholder dilutionmedium
Equity-funded growth has increased the share count, and further issuances could dilute existing shareholders 12.
- Reliance on third parties for manufacturingmedium
Production and distribution depend on external suppliers, whose compliance problems could delay studies or commercialization 1.
Investment thesis
What would need to be true (bull case)
- If the monotherapy is approved, the company could become the first with a bladder-sparing treatment for part of the NMIBC population, a segment with large unmet needs 1.
- A positive PIVOT-006 result could extend the target market to intermediate-risk patients, where no approved adjuvant therapy exists 12.
- Liquidity of about $1.0 billion and a funding horizon into 2029 could provide time to reach key milestones 3.
What would break the thesis
- Rising net losses and no product revenue could force further equity issuances, diluting shareholders 12.
- A failure or delay in the Phase 3 studies could weigh on investor confidence, since the company has no second candidate in development 1.
- Licence litigation and the regulatory requirements for live viruses could add costs and further delays 13.
What to watch
- Topline results of the PIVOT-006 Phase 3 study in intermediate-risk NMIBCQ3 2026
- Completion of the BLA submission for high-risk BCG-unresponsive NMIBCQ4 2026
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
The strategy aims for FDA approval of monotherapy in high-risk BCG-unresponsive NMIBC, based on the Phase 3 BOND-003 Cohort C study, with the Biologics License Application (BLA) expected to be completed in the fourth quarter of 2026 23. In parallel the company is extending the program to other indications, including the Phase 3 PIVOT-006 study in intermediate-risk NMIBC, where there are currently no FDA-approved adjuvant options in the frontline setting 1. Commercial readiness includes an in-house organization, and administration by nurses or medical assistants could avoid the need for urologists or anesthesia 1.
Segments
High-risk BCG-unresponsive NMIBC
This is the company's core segment, where the BOND-003 Cohort C study reported a 75.5% complete response rate with monotherapy, and the data were published in The Lancet Oncology in July 2026 12. The segment includes up to 25,000 addressable US patients and is the basis of the BLA submission 1.
Intermediate-risk NMIBC
The indication covers adjuvant treatment after transurethral resection, a segment of up to 50,000 addressable patients, for which enrollment in the Phase 3 PIVOT-006 study was completed in the third quarter of 2025 1. Topline results are anticipated soon, and a positive outcome could significantly widen the target market 23.
Market context
NMIBC accounts for about 75% of newly diagnosed cases, and cystectomy remains the guideline treatment after BCG failure, yet only about 6% of patients elect it, suggesting strong interest in bladder-sparing therapies 1. If the BLA is approved, the product could occupy an important therapeutic space, although timing and regulatory outcomes remain uncertain 12.
Trends
- Global BCG shortagetailwind
The persistent lack of BCG pushes physicians toward alternatives, including for intermediate-risk patients for whom guidelines no longer recommend BCG 1. This could create demand for new therapies if they are approved.
- Patient reluctance to undergo cystectomytailwind
Patients generally avoid removal of the bladder, which supports interest in organ-sparing treatments, but adoption could be limited if safety or efficacy data are judged insufficient 1.
- Regulatory requirements for live modified virusesheadwind
Cretostimogene is a live, gene-modified virus, and the FDA and other authorities apply additional safety and contagion rules that could delay approval and manufacturing 1.
- Access to capital marketsmixed
The company has funded itself through public offerings and at-the-market sales, but if market conditions deteriorate, capital could become more expensive while losses keep growing 12.
Competitive position
The market includes approved therapies, notably BCG, and other options against which the company compares itself; Imlygic has already been approved as an oncolytic viral immunotherapy in other indications, while few companies hold approved NMIBC products 1. The company points to simple administration, its safety profile and combination potential with pembrolizumab, which produced an 82.9% complete response rate in the CORE-001 study 1.
Competition also turns on the number of urology practices, since the product could be given in clinics that already use BCG, which could speed adoption if the FDA approves it 1. The company notes, however, that comparisons depend on final results from ongoing studies 23.
- Amgen (Imlygic)AMGN
The oncolytic viral therapy talimogene laherparepvec, FDA-approved, is cited as the first approved oncolytic viral immunotherapy, but in indications other than NMIBC 1.
- Standard BCG therapy
The reference treatment for high-risk NMIBC, affected by a shortage that limits patient access to this option 1.
- Pembrolizumab (checkpoint inhibitor)
Agent cited in combination with cretostimogene in the CORE-001 study in BCG-unresponsive NMIBC, not as a direct competing product 1.
- Radical cystectomy
The standard surgical procedure after BCG failure, which is the alternative the company seeks to help patients avoid 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Quarterly report06 Aug 2026
- Current report06 Aug 2026Results of operations · Other events · Financial statements and exhibits
- Current report08 Jun 2026Shareholder vote
- Current report26 May 2026Departure or appointment of officers
- Quarterly report08 May 2026
- Current report08 May 2026Results of operations · Financial statements and exhibits
- Proxy statement24 Apr 2026
- Current report13 Apr 2026Departure or appointment of officers · Financial statements and exhibits
- Annual report27 Feb 2026
- Current report27 Feb 2026Results of operations · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / CG Oncology, Inc. · 27 Feb 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / CG Oncology, Inc. · 06 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / CG Oncology, Inc. · 06 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.